

Stefano Luminari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1651240/publications.pdf>

Version: 2024-02-01

257
papers

9,972
citations

44042

48
h-index

40954

93
g-index

269
all docs

269
docs citations

269
times ranked

8555
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Interim 2-[¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3746-3752.	0.8	799
2	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016, 374, 2419-2429.	13.9	629
3	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613
4	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
5	Pure Red-Cell Aplasia and Epoetin Therapy. <i>New England Journal of Medicine</i> , 2004, 351, 1403-1408.	13.9	398
6	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.	0.8	287
7	ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 805-811.	0.8	256
8	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	0.8	231
9	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014, 99, 1107-1113.	1.7	225
10	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
11	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	1.7	213
12	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1113-1122.	3.3	152
13	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016, 127, 1531-1538.	0.6	143
14	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	2.2	138
15	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
16	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
17	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLLO5 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
18	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	1.2	122

#	ARTICLE	IF	CITATIONS
19	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	0.8	107
20	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
21	High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2320-2325.	0.8	106
22	Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i> , 2005, 106, 3343-3347.	0.6	101
23	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	3.2	94
24	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	0.8	94
25	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008, 93, 398-404.	1.7	92
26	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3293-3299.	0.8	90
27	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 56-64.	0.6	86
28	Nonpegylated liposomal doxorubicin (Myocet [®]) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. <i>Annals of Oncology</i> , 2010, 21, 1492-1499.	0.6	81
29	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. <i>Blood</i> , 1999, 93, 1330-1337.	0.6	80
30	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. <i>British Journal of Haematology</i> , 2013, 163, 40-46.	1.2	80
31	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
32	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
33	Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2005, 23, 4662-4668.	0.8	73
34	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
35	Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. <i>Haematologica</i> , 2011, 96, 720-728.	1.7	68
36	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67

#	ARTICLE	IF	CITATIONS
37	High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. <i>Haematologica</i> , 2009, 94, 146-148.	1.7	66
38	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
39	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011, 22, 689-695.	0.6	64
40	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
41	Cancer incidence in people with AIDS in Italy. <i>International Journal of Cancer</i> , 2010, 127, 1437-1445.	2.3	61
42	GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. <i>Cytotherapy</i> , 2010, 12, 466-477.	0.3	59
43	<i>Helicobacter pylori</i> eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860.	0.6	58
44	Transformed follicular lymphoma. <i>Annals of Hematology</i> , 2018, 97, 17-29.	0.8	58
45	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. <i>Blood</i> , 2001, 98, 781-786.	0.6	55
46	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	1.7	55
47	Decreasing incidence of gastric MALT lymphomas in the era of anti- <i>Helicobacter pylori</i> interventions: results from a population-based study on extranodal marginal zone lymphomas. <i>Annals of Oncology</i> , 2010, 21, 855-859.	0.6	53
48	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	0.6	53
49	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007, 109, 2077-2082.	2.0	50
50	Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. <i>Hematological Oncology</i> , 2007, 25, 189-197.	0.8	49
51	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018, 131, 2449-2453.	0.6	49
52	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	0.8	47
53	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
54	Infections occurring in adult patients receiving mechanical circulatory support: The two-year experience of an Italian National Referral Tertiary Care Center. <i>Medicina Intensiva</i> , 2013, 37, 468-475.	0.4	42

#	ARTICLE	IF	CITATIONS
55	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
56	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. <i>Blood</i> , 2015, 126, 733-738.	0.6	39
57	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISSI study. <i>Haematologica</i> , 2007, 92, 1482-1488.	1.7	38
58	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017, 102, 1748-1757.	1.7	38
59	T-Cell Lymphomas in South America and Europe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 42-47.	0.7	38
60	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	1.1	37
61	FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma. <i>Blood</i> , 1998, 92, 2987-2989.	0.6	36
62	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18-year follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014, 93, 221-231.	0.8	36
63	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e66-e68.	1.7	36
64	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	1.9	36
65	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	0.8	34
66	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
67	Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA. <i>Journal of Clinical Oncology</i> , 2018, 36, 7574-7574.	0.8	33
68	Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Rye's Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR). <i>Journal of General Internal Medicine</i> , 2012, 27, 1697-1703.	1.3	31
69	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2014, 166, 140-142.	1.2	31
70	Bendamustine salvage therapy for T cell neoplasms. <i>Annals of Hematology</i> , 2013, 92, 1249-1254.	0.8	30
71	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28
72	Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1249-1254.	2.8	27

#	ARTICLE	IF	CITATIONS
73	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1615-1621.	1.8	27
74	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 136-140.	2.5	27
75	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 393-393.	0.6	26
76	Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow. <i>Annals of Hematology</i> , 1998, 76, 81-83.	0.8	25
77	A multicenter retrospective clinical study of CD5/CD10 ϵ negative chronic B cell leukemias. <i>American Journal of Hematology</i> , 2008, 83, 349-354.	2.0	25
78	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3281-3287.	0.6	25
79	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. <i>Leukemia Research</i> , 2013, 37, 619-623.	0.4	24
80	Texture analysis and multiple-instance learning for the classification of malignant lymphomas. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 185, 105153.	2.6	24
81	Follicular lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 54-59.	0.7	24
82	Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003, 21, 1459-1465.	0.8	23
83	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	0.6	23
84	Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2319-2327.	0.6	23
85	Germinotropic lymphoproliferative disorder: a systematic review. <i>Annals of Hematology</i> , 2020, 99, 2243-2253.	0.8	23
86	Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. <i>Leukemia</i> , 2000, 14, 446-448.	3.3	22
87	BCL10 gene mutations rarely occur in lymphoid malignancies. <i>Leukemia</i> , 2000, 14, 905-908.	3.3	22
88	Survival of cancer patients in Italy. <i>Epidemiologia E Prevenzione</i> , 2017, 41, 1-244.	1.1	22
89	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	0.6	21
90	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	1.7	21

#	ARTICLE	IF	CITATIONS
91	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	1.3	21
92	Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. <i>Haematologica</i> , 2004, 89, 973-8.	1.7	21
93	Clinical characteristics of erythropoietin-associated pure red cell aplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 467-472.	0.7	20
94	Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 481-489.	0.7	20
95	The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Bone Marrow Transplantation</i> , 2006, 37, 283-288.	1.3	20
96	Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 367-373.	0.6	20
97	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq1 1 0,784314 rgBT /Ove	0,4	20
98	Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2005, 106, 5057-5057.	0.6	20
99	The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study. <i>BMC Cancer</i> , 2018, 18, 1069.	1.1	19
100	Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. <i>Hematological Oncology</i> , 2022, 40, 645-657.	0.8	19
101	Anthracyclines: A Cornerstone in the Management of Non-Hodgkin's Lymphoma. <i>Hematology Reports</i> , 2011, 3, e4.	0.3	18
102	Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. <i>Oncologist</i> , 2019, 24, 537-548.	1.9	17
103	Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients. <i>Frontiers in Nutrition</i> , 2021, 8, 620696.	1.6	17
104	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
105	Prognosis of follicular lymphomas. <i>Hematological Oncology</i> , 2006, 24, 64-72.	0.8	16
106	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. <i>Hematological Oncology</i> , 2012, 30, 194-199.	0.8	16
107	Dismal outcome of cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry. <i>Hematological Oncology</i> , 2015, 33, 147-151.	0.8	16
108	PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). <i>Thrombosis Research</i> , 2016, 140, S177.	0.8	16

#	ARTICLE	IF	CITATIONS
109	Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review. <i>Cancers</i> , 2021, 13, 2790.	1.7	16
110	Nonpegylated liposomal doxorubicin combination regimen (COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	0.8	15
111	Fertility in female survivors of Hodgkin's lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 48-53.	0.7	15
112	Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. <i>Leukemia and Lymphoma</i> , 2006, 47, 473-479.	0.6	14
113	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	0.6	14
114	A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2014, 25, 2398-2404.	0.6	14
115	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	0.5	14
116	Low Suvmax Measured on Baseline FDG-PET/CT and Elevated \hat{I}^{22} Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies. <i>Blood</i> , 2016, 128, 1101-1101.	0.6	14
117	Prognostic factors in low-grade non-Hodgkin lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 202-210.	1.2	13
118	The use of frailty assessments in treating older adults with aggressive lymphomas. <i>British Journal of Haematology</i> , 2021, 194, 677-685.	1.2	13
119	Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy. <i>Blood</i> , 2008, 112, 3753-3753.	0.6	13
120	Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. <i>American Journal of Hematology</i> , 2009, 84, 850-852.	2.0	12
121	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 2564-2571.	0.6	12
122	Brentuximab vedotin followed by ABVD + \hat{a} radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016, 101, e139-e141.	1.7	12
123	Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e49-e52.	1.2	12
124	Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. <i>Blood</i> , 2015, 126, 2686-2686.	0.6	12
125	Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial by the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 811-811.	0.6	12
126	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12

#	ARTICLE	IF	CITATIONS
127	Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. <i>Hematological Oncology</i> , 2013, 31, 72-78.	0.8	11
128	A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 373-383.	3.2	11
129	Reassessments of ESAs for cancer treatment in the US and Europe. <i>Oncology</i> , 2010, 24, 260-8.	0.4	11
130	Prognostic tools in follicular lymphomas. <i>Expert Review of Hematology</i> , 2009, 2, 549-562.	1.0	10
131	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011, 90, 323-330.	0.8	10
132	Early palliative care in haematological patients: a systematic literature review. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, 395-403.	0.8	10
133	Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 398-398.	0.6	10
134	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	0.8	10
135	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 138-144.	1.4	9
136	Prognostic Assessment in Patients with Indolent B-Cell Lymphomas. <i>Scientific World Journal</i> , The, 2012, 2012, 1-5.	0.8	9
137	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 880-887.	0.6	9
138	Early palliative care versus standard care in haematologic cancer patients at their last active treatment: study protocol of a feasibility trial. <i>BMC Palliative Care</i> , 2020, 19, 53.	0.8	9
139	Prospective Study of Indolent Non-follicular Non-Hodgkin's Lymphoma: Validation of Gruppo Italiano Per Lo Studio Dei Linfomi (GISL) Prognostic Criteria for Watch and Wait Policy. <i>Leukemia and Lymphoma</i> , 2002, 43, 1933-1938.	0.6	8
140	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006, 76, 217-229.	1.1	8
141	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>=70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8
142	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-associated Indolent Non-Hodgkin Lymphomas: The BARt Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	0.8	8
143	Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2003, 121, 772-774.	1.2	7
144	ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. <i>Annals of Oncology</i> , 2008, 19, 763-768.	0.6	7

#	ARTICLE	IF	CITATIONS
145	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478.	2.0	7
146	Bleomycin, Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002, 43, 1795-1801.	0.6	6
147	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	2.0	6
148	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
149	Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2021, 39, 205-214.	0.8	6
150	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 293-303.	0.8	6
151	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. <i>Blood</i> , 2019, 134, 124-124.	0.6	6
152	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. <i>British Journal of Haematology</i> , 2003, 123, 747-748.	1.2	5
153	The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). <i>Annals of Oncology</i> , 2006, 17, 676-682.	0.6	5
154	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. <i>Oncology Reports</i> , 2009, 21, 1029-35.	1.2	5
155	Home care of acute leukaemia patients: From active therapy to end-of-life and palliative care. The 3-year experience of a single centre. <i>European Journal of Haematology</i> , 2019, 102, 424-431.	1.1	5
156	Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. <i>British Journal of Haematology</i> , 2019, 185, 944-947.	1.2	5
157	Advances in Treatment of Follicular Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 231-240.	1.0	5
158	Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2019, 134, 2880-2880.	0.6	5
159	Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	0.6	5
160	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8006-8006.	0.8	5
161	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8507-8507.	0.8	5
162	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. <i>Frontiers in Oncology</i> , 2021, 11, 789891.	1.3	5

#	ARTICLE	IF	CITATIONS
163	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1689-1696.	0.6	4
164	Veno-occlusive disease nurse management: development of a dynamic monitoring tool by the GITMO nursing group. <i>Ecancermedalscience</i> , 2016, 10, 661.	0.6	4
165	Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy. <i>Hematological Oncology</i> , 2017, 35, 861-863.	0.8	4
166	A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7568-TPS7568.	0.8	4
167	What's new in peripheral T-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 52-60.	0.8	4
168	R-CHOP vs R-mini-CEOP in Elderly Patients with Diffuse Large B Cell Lymphoma: An Interim Report from Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2005, 106, 4729-4729.	0.6	4
169	Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study. <i>Blood</i> , 2007, 110, 1293-1293.	0.6	4
170	Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL. <i>Blood</i> , 2008, 112, 3050-3050.	0.6	4
171	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8552-8552.	0.8	4
172	Pretransplantation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 3707-3707.	0.6	4
173	Analysis of BCL-10 gene mutations in ovarian cancer cell lines. <i>Annals of Oncology</i> , 1999, 10, 1259.	0.6	3
174	Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 406-410.	0.6	3
175	Bridging the gap between epidemiology and clinical research in lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1855-1856.	0.6	3
176	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.	2.0	3
177	FDG-PET(CT)-adapted trials in non-Hodgkin lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 295-307.	1.1	3
178	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 920-923.	0.8	3
179	Renewed interest for low-dose radiation therapy in follicular lymphomas: From biology to clinical applications. <i>Hematological Oncology</i> , 2018, 36, 723-732.	0.8	3
180	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.0	3

#	ARTICLE	IF	CITATIONS
181	Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial.. Blood, 2006, 108, 2434-2434.	0.6	3
182	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. Blood, 2014, 124, 3088-3088.	0.6	3
183	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. Leukemia and Lymphoma, 2010, 51, 422-429.	0.6	2
184	Case Studies of Elderly Patients with Non-Hodgkin's Lymphoma. Hematology Reports, 2011, 3, e7.	0.3	2
185	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 247-251.	0.7	2
186	New information flows for cancer registries: testing the use of laboratory data in the province of Reggio Emilia, Italy. European Journal of Cancer Prevention, 2020, 29, 548-555.	0.6	2
187	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. British Journal of Haematology, 2021, 192, 1011-1014.	1.2	2
188	Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL). Blood, 2008, 112, 2602-2602.	0.6	2
189	Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients.. Blood, 2010, 116, 2821-2821.	0.6	2
190	FDG-PET and Hodgkin Lymphoma: Are We Ready for a Functional Tumor Volume Definition?. Blood, 2011, 118, 5187-5187.	0.6	2
191	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). Blood, 2013, 122, 3049-3049.	0.6	2
192	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3049-3049.	0.6	2
193	Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). Blood, 2021, 138, 305-305.	0.6	2
194	Splenosis peritonei. British Journal of Haematology, 2003, 123, 378-378.	1.2	1
195	A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). Annals of Oncology, 2016, 27, vi316.	0.6	1
196	Reply to T.P. Vassilakopoulos et al. Journal of Clinical Oncology, 2016, 34, 3585-3586.	0.8	1
197	Personalised approach in follicular lymphoma. Lancet Oncology, The, 2018, 19, 1431-1432.	5.1	1
198	Novel prognostic tools that identify high-risk follicular lymphoma. HemaSphere, 2019, 3, 82-84.	1.2	1

#	ARTICLE	IF	CITATIONS
199	Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo", Supportive Care in Cancer, 2020, 28, 5125-5137.	1.0	1
200	The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist, 2021, 26, e1418-e1426.	1.9	1
201	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. Blood, 2007, 110, 3429-3429.	0.6	1
202	Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas. Blood, 2010, 116, 1801-1801.	0.6	1
203	The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry. Blood, 2012, 120, 1611-1611.	0.6	1
204	The Role Of Qualitative FDG-PET Assessment Using The 5 Point Deauville Scale For Postinduction Response Assessment In Patients With Follicular Lymphoma. A Study From The Fondazione Italiana Linfomi (FIL). Blood, 2013, 122, 4295-4295.	0.6	1
205	Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi. Blood, 2014, 124, 499-499.	0.6	1
206	Outcome of Elderly Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Prospectively Identified by Comprehensive Geriatric Assessment (CGA). Results From a Study of the Intergruppo Italiano Linfomi (IIL). Blood, 2010, 116, 1771-1771.	0.6	1
207	Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori-Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-III Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial). Blood, 2011, 118, 958-958.	0.6	1
208	Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Blood, 2016, 128, 690-690.	0.6	1
209	Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi. Blood, 2018, 132, 2066-2066.	0.6	1
210	inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.. Journal of Clinical Oncology, 2022, 40, TPS7583-TPS7583.	0.8	1
211	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to mileshkin et al.. British Journal of Haematology, 2003, 123, 748-748.	1.2	0
212	The role of anthracyclines in follicular lymphomas. Leukemia and Lymphoma, 2006, 47, 2267-2268.	0.6	0
213	Positron emission tomography-computed tomography in follicular lymphoma: "one fit for all". Leukemia and Lymphoma, 2015, 56, 1191-1192.	0.6	0
214	New IMiD on the block. Lancet Haematology, the, 2020, 7, e627-e629.	2.2	0
215	Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. Bone Marrow Transplantation, 2020, 55, 2350-2353.	1.3	0
216	PET Imaging. Hematologic Malignancies, 2021, , 41-49.	0.2	0

#	ARTICLE	IF	CITATIONS
217	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).. Blood, 2004, 104, 3261-3261.	0.6	0
218	Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.. Blood, 2006, 108, 4628-4628.	0.6	0
219	Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. Blood, 2006, 108, 4703-4703.	0.6	0
220	Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.. Blood, 2006, 108, 2442-2442.	0.6	0
221	Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.. Blood, 2006, 108, 2763-2763.	0.6	0
222	IELSG Phase II Studies of Bortezomib in Malt Lymphomas.. Blood, 2007, 110, 2580-2580.	0.6	0
223	Front-Line Treatment of Low-Grade Non-Follicular Non-Hodgkin Lymphoma (Final Report of Gisl LL02) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	0
224	The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features.. Blood, 2007, 110, 2077-2077.	0.6	0
225	Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients.. Blood, 2008, 112, 1012-1012.	0.6	0
226	A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection. Blood, 2008, 112, 3054-3054.	0.6	0
227	Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative.. Blood, 2009, 114, 1259-1259.	0.6	0
228	Use of FDG Positron Emission Tomography (FDG-PET) in Patients with Hodgkin Lymphoma (HL): a Population Based Study.. Blood, 2009, 114, 5023-5023.	0.6	0
229	Incidence Rate of Thromboembolic Events (TE) In a Prospectively Evaluated Population of Patients with Lymphoma Enrolled In First Line Treatment Clinical Trials: a Report From the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). Blood, 2010, 116, 4208-4208.	0.6	0
230	Prolonged Survival with Low Incidence of CNS Relapse and Late Toxicities in a Retrospective Series of 278 Young Patients with High-Risk (aa-IP1 2â€“3) Diffuse Large B-Cell Lymphoma Treated with Intensified Chemotherapy with or without Rituximab At Diagnosis. Blood, 2011, 118, 1606-1606.	0.6	0
231	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2651-2651.	0.6	0
232	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2636-2636.	0.6	0
233	What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study â€œRefollâ€“by the Fondazione Italiana Linfomi (FIL) On 548 Patients. Blood, 2012, 120, 154-154.	0.6	0
234	Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet â„¢) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970). Blood, 2012, 120, 3644-3644.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Bendamustine Salvage Therapy for T-Cell Non Hodgkin Lymphoma. Blood, 2012, 120, 4860-4860.	0.6	0
236	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. Blood, 2012, 120, 2647-2647.	0.6	0
237	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 3653-3653.	0.6	0
238	Addition of Rituximab to Front-Line-Treatment Highly Improved the Outcome of Elderly Patients with Follicular Lymphoma: a Population Based-Study From the Modena Cancer Registry. Blood, 2012, 120, 5077-5077.	0.6	0
239	Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 3652-3652.	0.6	0
240	Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. Blood, 2013, 122, 5088-5088.	0.6	0
241	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. Blood, 2013, 122, 1782-1782.	0.6	0
242	Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. Journal of Clinical Oncology, 2014, 32, 8530-8530.	0.8	0
243	Prognostic value of PET-CT after frontline therapy in follicular lymphoma: A pooled analysis of central review in three multicenter studies.. Journal of Clinical Oncology, 2014, 32, 8502-8502.	0.8	0
244	Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry. Blood, 2014, 124, 5400-5400.	0.6	0
245	Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases. Blood, 2014, 124, 5411-5411.	0.6	0
246	Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL. Blood, 2014, 124, 4429-4429.	0.6	0
247	Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Treated with Chemo-Immunotherapy. Blood, 2014, 124, 3027-3027.	0.6	0
248	Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study. Blood, 2015, 126, 5032-5032.	0.6	0
249	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. Blood, 2015, 126, 3919-3919.	0.6	0
250	Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma. Blood, 2015, 126, 581-581.	0.6	0
251	Identification of a Novel Gene Expression Signature in Mantle Cell Lymphoma from the Fondazione Italiana Linfomi (FIL)-MCL-0208 Trial: A Focus on the B Cell Receptor Pathway. Blood, 2015, 126, 701-701.	0.6	0
252	Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine,) Tj ETQq0 0 0 rgBT /Overlock 10 T Relapsed/Refractory Classic Hodgkin Lymphoma. Blood, 2018, 132, 1628-1628.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Home Care of Acute Leukemia Patients: From Active Therapy to End-of-Life and Palliative Care. a Three-Year Experience of a Single Centre. <i>Blood</i> , 2018, 132, 5867-5867.	0.6	0
254	Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. <i>Blood</i> , 2019, 134, 1539-1539.	0.6	0
255	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. <i>Blood</i> , 2021, 138, 41-41.	0.6	0
256	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
257	Reply to M. Shibusawa et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200177.	0.8	0